Market capitalization | $3.17b |
Enterprise Value | $3.09b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 18.01 |
P/S ratio (TTM) P/S ratio | 18.49 |
P/B ratio (TTM) P/B ratio | 6.86 |
Sales growth (TTM) Sales growth | 18.74% |
Turnover (TTM) Turnover | $171.34m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
4 Analysts have issued a Olink Holding AB (publ) - ADR forecast:
4 Analysts have issued a Olink Holding AB (publ) - ADR forecast:
Dec '23 |
+/-
%
|
||
Net profit | -32 -32 |
147%
147%
|
|
Depreciation and amortization | 19 19 |
10%
10%
|
|
Share compensation | 11 11 |
40%
40%
|
|
Operating cash flow | -30 -30 |
0%
0%
|
|
Investments | 21 21 |
149%
149%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -49 -49 |
32%
32%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Olink Holding AB engages in developing and expanding its platform of immunoassay panels for protein biomarker discovery. It enables and accelerates the field of proteomics by providing a platform of products and services, developed with key opinion leaders (KOLs), that are deployed across biopharmaceutical companies. The company was founded on December 13, 2018 and is headquartered in Uppsala, Sweden.
Head office | Sweden |
CEO | Jon Heimer |
Employees | 707 |
Founded | 2019 |
Website | www.olink.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.